Reviewer's report

**Title:** Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers

**Version:** 2  
**Date:** 17 December 2014

**Reviewer:** Howard Burris

**Reviewer's report:**

The manuscript in general is well-written. The advances in hormonal therapy are included, but there are some overlooked agents. A number of PI3K/TORC inhibitors are in development with trial results reported. Inclusion of the recent "FERGIE" data with GDC0941 would be useful. There are also other CDK 4/6 inhibitors with results and key ongoing studies. Lastly the novel compounds could be briefly addressed. It seems that combination hormone therapy and/or the use of HDACs such as etinostat are less interesting to the reader than the novel biologics.

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests.